pre-IPO PHARMA

COMPANY OVERVIEW

Dyno Therapeutics is a pioneer in applying artificial intelligence to gene therapy. The company’s powerful and proprietary genetic engineering platform is designed to rapidly and systematically develop improved AAV capsids that redefine the gene therapy landscape. Dyno was founded by experienced biotech entrepreneurs and leading scientists in the fields of synthetic biology, gene therapy, and machine learning. The company is located in Cambridge, Massachusetts.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS


    WEBSITE

    https://www.dynotx.com


    CAREER WEBSITE

    https://www.dynotx.com/careers


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    May 19, 2023

    Dyno Therapeutics Launches the Dyno bCap 1™ Capsid Product, a Breakthrough CNS Gene Delivery Vector Created with Generative Artificial Intelligence


    May 2, 2023

    Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)


    Dec 1, 2021

    Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle


    May 11, 2021

    Dyno Therapeutics Presents State-of-the-Art Applications of Machine Learning to Design Improved AAV Capsids for a Broad Range of Gene Therapies at American Society of Gene and Cell Therapy Conference


    May 6, 2021

    Dyno Therapeutics Closes $100 Million Series A Financing Led by Andreessen Horowitz to Accelerate AI‑powered Gene Therapy Platform


    For More Press Releases


    Google Analytics Alternative